Peer-influenced content. Sources you trust. No registration required. This is HCN.
Blood Advances
This “Clinical Trials & Observations” report from Blood Advances (ASH) explores the implications of the recently approved anemia treatment luspatercept, which can now be prescribed in the second-line setting after erythropoiesis-stimulating agents (ESAs) have failed or for patients who are not eligible because of high serum erythropoietin (sEPO) levels. A downloadable visual abstract helps paint the picture as well.
Hematology March 16th 2021
ASH Clinical News speaks with Maureen Achebe, MD, MPH, Clinical Director of the Non-Malignant Hematology Clinic at Brigham and Women’s Hospital in Boston, and other experts, about the safety and efficacy of IV iron products, how they are perceived in the community, and barriers to their use in the clinic.
Family Medicine/General Practice October 19th 2020
DIET & NUTRITION 
PATIENT EDUCATION 
OBESITY/WEIGHT MANAGEMENT 
EXERCISE/TRAINING 
LEGAL MATTERS 
GUIDELINES/RECOMMENDATIONS